Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.76 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.76 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.76 |
| ▸ | CDK2 | P24941 | 2/20 | 0.76 |
| ▸ | CDK7 | P50613 | 2/20 | 0.76 |
| ▸ | CCNH | P51946 | 2/20 | 0.76 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.76 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.76 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762909 | 0.90 | PGR (0.77) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL12113068 | 0.86 | MEN1 (0.78) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL5894008 | 0.86 | CDK1 (0.74) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL22516007 | 0.86 | CDK1 (0.74) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL6842347 | 0.85 | FFAR1 (0.77) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL22441723 | 0.85 | CDK1 (0.64) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL678551 | 0.84 | CA1 (0.65) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL27179684 | 0.83 | LMNA (0.70) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL30926925 | 0.83 | LMNA (0.70) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL27912548 | 0.83 | FFAR4 (0.69) | CDK1CCNB1CCNA2CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176426-A1 | FXR modulators | TULARIK, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-6777446-B2 | FARNESOID X RECEPTOR; TREATING DISEASES ASSOCIATED WITH ABNORMALLY HIGH OR LOW CHOLESTEROL LEVELS. | TULARIK, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | TULARIK INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002020463-A2 | FXR MODULATORS | TULARIK INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | NR1H4, NR1H2, NR1H3 | CDK1 4629/4885CCNB1 4433/4885CCNA2 4834/4885 |
| US-20040176426-A1 | FXR modulators | NR1H4, CYP7A1, CYP7B1 | CDK1 4495/4885CCNB1 4242/4885CCNA2 4752/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | CDK1 1947/4885CCNB1 2750/4885CCNA2 3774/4885 |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | CDK1 3126/4885CCNB1 4557/4885CCNA2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.